I USE LR in the ED

Intermountain Health Care, Inc.200,000 enrolled

Overview

To study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.

Study Type

OBSERVATIONAL

Enrollment

200,000

Conditions

Kidney Injury

Interventions

Data InclusionOTHER

Patients in this group will be included in the project

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥18 years) receiving a minimum of 1000ml of intravenous fluids starting in the emergency department per standard of care Exclusion Criteria: * Patients aged ≤17 years * Previously enrolled patients with \>1 ED admission within the 30-day follow-up period

Locations (1)

Intermountain Medical Center

Murray, Utah, United States

Outcomes

Primary Outcomes

Number of participants with major Adverse Kidney Events

death from any cause, new renal replacement therapy or persistent renal dysfunction

Time frame: within 30 days or at hospital discharge

LR IV Fluids administered

Proportion of LR IV fluids following implementation

Time frame: Through study completion (an average of 1 year)

Secondary Outcomes

Rate of hospital admission and readmission

Time frame: Within 30 days of initial ED encounter

Cost

Direct costs of ED care and hospitalization

Time frame: Through study completion (an average of 1 year)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.